6-Chloro-5-methyl-N-(6-((2-methylpyridin-3-yl)oxy)pyridin-3-yl)indoline-1-carboxamide dihydrochloride
CAS : 181632-25-7
Ref. 3D-GHA63225
3g | Arrêté | ||
Taille indéfinie | Arrêté |
Informations sur le produit
- 1H-Indole-1-carboxamide, 6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-
- 6-Chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxamide
- 6-Chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride
- 6-Chloro-5-methyl-1-[(2-[2-methylpyrid-3-yloxy]pyrid-5yl)carbamoyl]indoline dihydrochloride
- SB242084 diHCl
- SB242084 hydrate dihydrochloride
- Sb 242084
Aniracetam is an activated form of the amino acid, lecithin. It is a drug that belongs to the class of nootropics and has been used in treating dravet syndrome. Aniracetam is a modulating agent for autophagy, which is a process in which cells degrade their own cellular components by catabolic pathways. This drug has been shown to increase macroautophagy in mice by causing activation of the 5-HT2C receptor. Aniracetam also increases the activity of chaperones, which are proteins that help maintain protein homeostasis. The nature of this drug's pharmacokinetic properties is nonselective, meaning that it does not discriminate between classes of receptors or channels.